FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/08/2023
Voltar para busca
Dado oficial do USPTO
KELIX BIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
14/08/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
02/09/2021
Data de registro
11/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/04/2023
Última transação
11/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
EINSTEIN, MATTHEW T
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Kelix Bio Limited
Representantes
Alexander Lazouski LAZOUSKI IP LLC
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals and natural remediespharmaceutical preparations for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; medical preparations for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; injectable pharmaceuticals for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; injectable dermal fillers; biological preparations for medical purposespharmaceutical preparations for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; pharmaceutical preparations for inhalers for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; vitamins; medicinal preparations for the treatment of infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; diagnostic preparations and materialsdiagnostic agentspreparations and substances for medical purposes; respiratory stimulants; compoundsmedicine for treating respiratory diseases; pharmaceutical products for treating respiratory diseases; dermatological pharmaceutical products
Classe 10
Medical apparatus and instruments for treating infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; medical instruments for treating infectiousmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalnephrologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricblood disorderslymphatic system and immune system related diseases and disorders; inhalers for therapeutic use; medical inhalersinhalers for medical use; physical therapy equipment in the nature of foam rollersmanually-operated resistance tubingweighted balls
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/07/2023
FIMP
FINAL DISPOSITION PROCESSED
26/07/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
24/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/01/2023
PUBO
PUBLISHED FOR OPPOSITION
24/01/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/12/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
19/12/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
19/12/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
19/12/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
19/12/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/12/2022
RFNT
REFUSAL PROCESSED BY IB
13/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/06/2022
RFRR
REFUSAL PROCESSED BY MPU
16/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/06/2022
CNRT
NON-FINAL ACTION WRITTEN
13/06/2022
DOCK
ASSIGNED TO EXAMINER
08/06/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/12/2021
MAFR
APPLICATION FILING RECEIPT MAILED
16/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KELIX BIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.